The origins of Innogene (WA:IGNP) go back to 2005, when two scientists from the Polish Academy of Science (PAN) founded a company in order to commercialize scientific research in the area of biotechnology. Today, Inno-Gene acts as a holding, which invests in and supports promising projects in the area of diagnostic genetics. With an offering of >400 tests including >100 own ones, its 100% shareholding Centrum Badan DNA Sp. z.o.o is one of the leading players on the Polish market.
Through two direct and three indirect subsidiaries, Inno-Gene provides a full scope of services relating to diagnostic testing e.g. tests for medical and veterinary facilities, law enforcement agencies as well as private individuals, DNA sequencing for scientific institutions, research on new tests in own labs funded by EU subsidies, trainings, test analysis with respective software. Its most promising test, which is considered revolutionary by many Polish scientists, is a universal diagnostic panel that allows detecting genetic predispositions to >20 kinds of cancer.
According to independent market research firms, the global market for genetic diagnostics is set to grow at a fast pace in the coming years as these tests can potentially save lives and significantly reduce health costs. Market forecasts show the total market value at USD 5.6-6.9bn and the yearly growth rate in the coming years at 16.1%-17.5%. Based on our discussions with industry experts, for Poland we estimate the total market value at c. PLN 80m, however forecast a much faster growth going forward of >50% y-o-y due to the early-stage character of the market.
East Value Research GmbH has taken several measures to prevent conflicts of interest. One of these is that its employees are prohibited to trade in stocks from its coverage.
In addition, its employees are not permitted to accept gifts or any other beneficial contributions from individuals, who have an interest in the content of our research publications.